Natera stock is trading -12.19% below its average target price of $191.51 after marking a 5.0% during today's afternoon session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $37.0 to $251.0 per share.
The stock has an average amount of shares sold short at 4.5%, and a short ratio of 4.8. The company's insiders own 3.25% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.3% of Natera's shares being owned by this investor type.
Institutions Invested in Natera
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 9% | 12,393,827 | $2,084,083,964 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 8% | 10,537,743 | $1,771,974,161 |
| 2025-03-31 | Blackrock Inc. | 8% | 10,440,588 | $1,755,637,062 |
| 2025-03-31 | JPMORGAN CHASE & CO | 5% | 7,361,963 | $1,237,950,879 |
| 2025-03-31 | Farallon Capital Management LLC | 3% | 4,547,809 | $764,736,816 |
| 2025-03-31 | Duquesne Family Office Llc | 2% | 3,402,330 | $572,118,796 |
| 2025-03-31 | State Street Corporation | 2% | 3,370,551 | $566,774,999 |
| 2025-03-31 | Wellington Management Group, LLP | 2% | 3,059,688 | $514,501,831 |
| 2025-03-31 | Fred Alger Management, LLC | 2% | 2,604,160 | $437,902,521 |
| 2025-03-31 | RTW Investments LP | 2% | 2,593,546 | $436,117,724 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Natera.
